Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 5/20 | 0.50 |
| ▸ | CES1 | P23141 | 4/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4460608 | 0.86 | CES2 (0.48) | CES2CES1AKR1B1MEN1FAAH | |
| SCHEMBL136825 | 0.85 | CES2 (0.38) | CES2CES1ALDH1A1TSHR | |
| SCHEMBL7663036 | 0.84 | CES2 (0.52) | CES2CES1 | |
| SCHEMBL11229618 | 0.84 | CES2 (0.52) | CES2CES1 | |
| SCHEMBL9868874 | 0.84 | CES2 (0.52) | CES2CES1 | |
| SCHEMBL4958852 | 0.84 | CES2 (0.52) | CES2CES1 | |
| SCHEMBL9119248 | 0.84 | CES2 (0.52) | CES2CES1 | |
| SCHEMBL10722450 | 0.84 | CES2 (0.52) | CES2CES1 | |
| SCHEMBL8917791 | 0.84 | CES2 (0.52) | CES2CES1 | |
| SCHEMBL11540653 | 0.84 | CES2 (0.52) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106794681-B | Resist the multilayer middle layer that defect is formed | 首诺公司 | 2019-10-22 | — | — | CN | disclosed |
| CN-106794681-A | The multilayer intermediate layer that resistance defect is formed | 首诺公司 | 2017-05-31 | — | — | CN | disclosed |
| US-20050182047-A1 | Treatment of demyelinating disorders | EISAI CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| US-20050130979-A1 | 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) or the quinoxalinedione is 9-methyl-amino-6-nitro-hexahydro-benzo(F) quinoxalinedione (PNQX) for treating demyelinating disorders | EISAI CO., LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| US-20040204347-A1 | Treatment of demyelinating disorders | EISAI CO., LTD. (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-1100504-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS | Eisai Co., Ltd. (JP) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000001376-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS | EISAI CO., LTD (JP) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204347-A1 | Treatment of demyelinating disorders | GRIK4, GRIK5, PMP22 | CES2 3024/4885CES1 2548/4885AKR1B1 2477/4885 |
| US-20050130979-A1 | 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) or the quinoxalinedione is 9-methyl-amino-6-nitro-hexahydro-benzo(F) quinoxalinedione (PNQX) for treating demyelinating disorders | GRIK4, GRIK5, GRIK3 | CES2 3967/4885CES1 3447/4885AKR1B1 1792/4885 |
| US-20050182047-A1 | Treatment of demyelinating disorders | GRIK4, PMP22, GRIK5 | CES2 2987/4885CES1 2596/4885AKR1B1 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.